Following its launch of the Global Million Clinical Study (GMCS), Seegene Inc. has announced a comprehensive syndromic PCR-based testing approach for reproductive tract infections (RTIs) through the simultaneous detection of sexually transmitted infections (STIs) and human papillomavirus (HPV).

The initiative aims to generate scientific evidence for Global New Standards of PCR testing by accumulating real-world clinical data from healthcare institutions worldwide and evaluating the clinical utility of disease-specific diagnostic testing strategies.

Using STAgora, Seegene's real-time test data analytics and statistical platform, the company internally analyzed approximately 60,000 HPV & STI co-testing results generated over a 42-month period. The analysis showed that STI pathogens were detected in 82% of HPV-positive cases, while HPV was detected in 46% of STI-positive cases. In addition, co-detection of HPV and STI pathogens was observed in 71% of positive cases identified through comprehensive HPV & STI testing.

These findings demonstrate the potential application of concurrent STI testing with HPV screening. The promising applications may include identifying asymptomatic STIs, assessing co-infections in HPV-positive individuals, and supporting reproductive health evaluations during pregnancy planning or infertility assessment.

Through GMCS, Seegene plans to continue accumulating clinical evidence on comprehensive HPV & STI testing and to statistically evaluate its clinical utility and applicability using STAgora.

Visit Seegene for more information